September 23, 2022 7:44am
Price of eggs = $2.74 for a dozen, share price of Applied Genetic Technologies (AGTC $0.29); price of OJ = $3.97 for 32 fluid ounces, share price of Avrobio (AVRO $0.72)
Which would you rather have, buy, rather as volatility drives equities lower and basic needs higher?
Indications: 2 Negative and 1 Positive Indications with 1 Pump/Promote (BSTG – the usual suspect)
The cell and gene therapy sector shows more signs of downside movement alternating to continued weakness.
No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -1.26% or (-379 points), S&P futures are DOWN -1.39% (-5 points) and NASDAQ futures are DOWN -1.52% (-176 points) early in the pre-open – so far,
Stock futures were lower on Friday to close out another losing week,
European markets in the red, as bank of England also hiked rates by 50 basis points and Credit Suisse leads the market downturn early morning after a report of a possible capital raise,
Asia Pacific markets were in the red, with Australian stocks down 2%.
Thursday brought another day of losses as the market remains poised to end the week below where it started
Friday will be the fourth (4th) straight daily decline, as fear the Fed’s rate hikes has pushed the market/economy into a recession.
The Dow closed DOWN -107.10 points (-0.35%) the S&P closed DOWN -31.94 points (-0.84%) while the Nasdaq closed DOWN 153.39 points (-1.77%)
RegMed Investors’ (RMi) closing bell: “short positions play the market’s volatility. Why are CEOs and management TEAMS NOT initiating defensive PERSONAL BUYS amid the persistent market volatility this year to boast their bottoming share pricing?” … https://www.regmedinvestors.com/articles/12616
Ebb and flow:
Q3/22 – September – 1 holiday, 7 positive and 8 negative closes
• August – 1 neutral, 11 positive and 11 negative closes
• July - 1 holiday, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Sage Therapeutics (SAGE) closed down -$0.66 to $39.22 with a negative -$1.96 or -5% pre-open indication.
Intellia Therapeutics (NTLA) closed down -$2.39 to $57.08 with a negative -$2.08 or -3.64% pre-open indication,
Beam Therapeutics (BEAM) closed down -$3.47 to $48.15 with a positive +$0.80 or +1.66% pre-open indication,
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) closed FLAT again with 1,844 shares traded on Thursday after Wednesday’s FLAT with 3,196 shares traded, Tuesday’s +$0.10 with 9,718 shares traded, <3-month average = 2,019>,
Questions need to be answered and they NEVER are for shareholders; as the First Amendment of the U.S. Constitution does guarantee the “freedom of speech, or of the press” … but I guess NOT to respond?
- How many non-citizens of Chinese nationality are employed at BSTG – 3 managers/directors of 5 and 3 of 5 board directors?
- Who, WHAT and WHERE are pumping and promoting the “spikes” in volume and share price … coming from?
- What is DST Capital? Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG? Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
- Are Chinese communist bureaucrats from Beijing, China directing the company’s activities with BSTG being their corporate “concubine”?
The BOTTOM LINE: The Fed policy announcement hurt portfolios: as I had been writing, it's a time for investors to have minimal exposure.
Especially with another quarter (Q3) about to close … and then back to earnings season – that’s LPS (loss-per-share) period!
I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!
When a cell and gene therapy sector equity sells-off to or below a buy point, investors face a tough decision: hold tight, exit or trim the position. There's not necessarily a "right" answer.
Equities always will bounce back; the question is WHEN and the cost of money lost in the current volatile market.
As I continually write, “The real question that should be asked is how many companies are at the end of sentiments … leash? Start by looking at cell and gene therapy companies trading below cash!”
When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.
As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”
That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.
Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.